For military personnel and veterans diagnosed with cancer, accessing specialised testing and treatment options can be difficult, particularly when care...
For millions of women living with endometriosis, persistent pain can disrupt daily life, affect fertility and limit treatment choices. Existing hormonal th...
Ambrose Healthcare’s acquisition of AM-Pharma, valued at up to €161 million plus royalties, strengthens its rare disease pipeline and establishe...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
Biopharma Boardroom speaks with Quentin Le Masne de Chermont, Head of Corporate Strategy and Business Development at Grünenthal Group, a...
Biopharma Boardroom speaks with Nadia Aelbrecht, Vice President, Head of Infectious Disease at QIAGEN, about rapid diagnostics, antimicrobial...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
Symbiosis Pharmaceutical Services is entering a new phase of growth following a £26 million investment to expand its ...
As biologics and novel modalities become increasingly sophisticated, understanding molecular structure under controlled conditions tells only part ...
For emerging biopharma companies, speed, quality and scalability cannot be treated as separate priorities. As products progress t...
Scientific breakthroughs are advancing rapidly across complex biologics, cell and gene therapies, radiopharmaceuticals and ADCs, but translating th...
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of ther...
As advanced therapies move from development towards commercial scale, quality is becoming far more than a regulatory checkpoint. It is increasingly...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
© 2026 Biopharma Boardroom. All Rights Reserved.
